跳至主要内容
临床试验/RBR-8w292w
RBR-8w292w进行中(未招募)2 期

Effect of fluconazole in the treatment of localized cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis: an open-label, phase two study with sequential dose-escalation groups

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado0 个研究点开始时间: 2017年5月3日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 90Y(—)
性别
Male

入选标准

  • Male patient with eighteen years of age or more; bearer of American cutaneous leishmaniasis; caused by Leishmanis (Viannia) guyanensis; with up to five lesions; with no more than three months; without any mucosal disease and no previous treatment of the current episode of leishmanisasis

排除标准

  • Exclusion criteria are: Refusal to participate in the project; Patients with liver disease; Patients with cardiac arrhythmias; Patients with hypertriglyceridemia; Patients with hypokalemia; recognized hypersensitivity to fluconazole; Presence of immunosuppression

研究者

发起方
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado

相似试验

Efficacy of Fluconazol in the Treatment of Cutaneous... | 临床试验